When a child's prescription gets stronger every year, the number on the prescription is not the problem. What it is measuring is.
Nearsightedness progresses because the eye is growing too long from front to back. The glasses correct the blur that causes. They do nothing about the growth, and it is the growth that raises the lifetime risk of retinal detachment, glaucoma and myopic macular degeneration.
No treatment reverses myopia. What the treatments do is reduce how much further it goes, and they only work while the eye is still growing. If your child's prescription changed noticeably at the last two exams, that is the conversation to have now rather than at the next one.
As the eye lengthens, the tissues lining the back of it stretch and thin with it. That thinning is the mechanism behind the adult risks, and it does not undo itself later. An adult with a strong prescription is not simply someone who needs thicker glasses; they are carrying a structurally different eye.
Each dioptre of myopia avoided is estimated to cut the lifetime risk of myopic macular degeneration by roughly 40 per cent, and the relationship holds across the range rather than only at the severe end. That is why a difference that sounds small on a prescription pad is not small.
It also explains the emphasis on starting early. The younger a child is when myopia begins, the more growing years remain for it to accumulate in, and the further it tends to end up. Years available to influence are the resource being spent here.
A glasses prescription is an indirect reading of eye length, and a coarse one. It can sit unchanged for a year while the eye keeps growing, which reads as success and is not. It also moves for reasons that have nothing to do with growth — how a child responds on the day, how much focusing effort they hold.
Axial length is the direct measurement. It is the actual front-to-back length of the eye, in millimetres, measured with a Topcon MYAH. It is precise enough that a treatment can be judged on months of data rather than years, and it can be plotted against the growth curve for a child of that age so the question becomes whether this eye is growing faster than it should be, not merely whether it grew.
Without it, deciding whether a treatment is working comes down to comparing two refractions and guessing. That is the single practical reason this is a distinct service rather than something folded into a routine exam.
Children are normally born slightly long-sighted and spend that reserve down as the eye grows through childhood. A child spending it faster than expected is on a path toward myopia, and that is visible in the numbers well before anything is blurry.
This matters most for a younger sibling of a child already in treatment. The family risk is already established, the sibling is in the age window where onset usually happens, and the things that influence onset — outdoor time in particular — work better as prevention than as treatment. There is no reason to wait for the first complaint about the board at school.
Two carry FDA authorization for slowing myopia progression in children, and both are offered here. A third is used selectively. Which one fits depends on the child's age, prescription, and whether they are ready for contact lenses — not on which has the largest number attached to it.
A spectacle lens, authorized in September 2025 for children aged 6 to 12 at the start of treatment — the first eyeglass lens cleared for this purpose in the United States. That age floor matters, because it reaches children younger than the contact lens option does, and it suits any child not ready to handle lenses.
They are worn and cared for like ordinary glasses. The centre of the lens carries the child's prescription; the surrounding zone carries a pattern that changes where light lands in front of the peripheral retina, which is the signal the eye responds to by slowing its growth.
What the trial found. In the two-year trial submitted for FDA authorization, children in Stellest lenses progressed 0.25 dioptres on average against 0.90 in single-vision lenses, a difference of 71 per cent, and their eyes grew 0.24 mm less, a difference of 53 per cent. Those are Essilor's figures from their own trial.
The effect depends on how much they are worn. A separate two-year trial found the benefit rising substantially in children who wore them twelve hours a day, every day. Glasses left in a bag do nothing, and that is worth saying to a child directly.
A daily disposable soft contact lens, FDA-approved for children aged 8 to 12 at the start of treatment. Worn during the day and thrown away at night, so there is no cleaning routine and no solution to forget. New wearers are taught insertion and removal in the office.
The lens has concentric zones: the centre corrects the child's vision, and the surrounding rings bring part of the light to focus in front of the peripheral retina, which is the same growth signal by a different route.
What the trial found. Over three years, children in MiSight progressed 0.51 dioptres on average against 1.24 in a single-vision daily lens, a difference of 59 per cent, with 0.32 mm less axial growth, a difference of 52 per cent. Those are CooperVision's figures from their own trial.
A drop at bedtime, used selectively where neither of the above is a fit — a prescription outside the authorized range, a child who will not wear lenses and will not keep the glasses on, or as an addition where progression continues despite one of them.
Two honest caveats. It is compounded rather than FDA-approved for myopia control, so concentration can vary between pharmacies and between batches in a way the two authorized products do not. And the evidence for the low concentrations used now is more recent than it is often made to sound: the trials that established them date from 2012 onward. The decades of atropine experience people cite belong to the 1 per cent concentration, which worked but left children light-sensitive and unable to focus up close, and is not what is used for this.
All of these figures are group averages from controlled trials. They describe what a population did, not what one child will do, and an authorization covering an age range does not make every child in that range a candidate. That gap is exactly what the measurement is for.
Two environmental factors influence how fast a child's eye grows, and neither costs anything.
Neither of these replaces treatment in a child who is already progressing. They are worth doing anyway, and in a younger sibling who has not started yet they are the part that matters most.
Until the eye stops growing, which for most children is somewhere in the mid to late teens. It is reviewed at every visit, and the axial length measurements are what show when growth has settled rather than a date decided in advance.
Stopping early does not make the eye spring back. What it does is hand the remaining growing years back to their untreated rate — which is the thing the treatment existed to slow, so the effect is the same as never having those years.
The eye examination goes through your vision plan or medical plan the same as any other exam. Myopia management is a separate service on top of that — the axial length measurements, the closer follow-up schedule, and the lenses themselves — and what a plan contributes to that part varies a great deal.
Call with your plan details before committing to anything and we will tell you where you stand beforehand rather than let you find out afterwards.
No. Orthokeratology — the rigid lens worn overnight to reshape the cornea — is a real myopia control option and it is not fitted here. If that is the route you want, say so and you will be pointed toward someone who does it.
Yes, and it is the check most worth doing. Children start out slightly long-sighted and spend that reserve down as the eye grows. A child spending it faster than expected is heading toward myopia before anything looks blurry, and measuring where they sit against the expected curve for their age shows it.
Finding out at that stage is the difference between preventing and slowing.
Age decides that more than the size of the change does. A small yearly change at fifteen is close to finished. The same change at seven has eight or nine growing years left to compound in and will not stay small.
This is also where axial length separates the two cases better than the prescription can, because a prescription can hold still for a year while the eye behind it keeps growing.
Yes, and most children who start here are already in glasses — the yearly increase is usually what brought it up. Starting later leaves fewer growing years to work with, so sooner is better, but there is no point at which it stops being worth doing while the eye is still growing.
A myopia evaluation is a different appointment from a routine eye exam. It adds the axial length measurement and the growth curve, and it ends with a decision about whether to treat and with what — not with a prescription and a follow-up in a year.
Call (609) 246-0236 or send a text
Text messages are not a secure channel. Use them to ask for a call back — not to describe symptoms, and not for photographs.
Khoury Eye Care, Hamilton Mall, 4403 Black Horse Pike, Mays Landing.
